|
|
| (5 intermediate revisions by the same user not shown) |
| Line 4: |
Line 4: |
| | <partinfo>BBa_K1431402 SequenceAndFeatures</partinfo> | | <partinfo>BBa_K1431402 SequenceAndFeatures</partinfo> |
| | | | |
| | + | === Designing the Sequence === |
| | | | |
| − | === Introduction ===
| + | We used a method derived from the method described in the paper by Feng Zhang<sup>[http://www.nature.com/nbt/journal/v31/n9/abs/nbt.2647.html ZhangFgRNA]</sup>. |
| | | | |
| − | '''CRISPR(Clustered Regularly Interspaced Short Palindromic Repeat)/Cas System''' is a hot topic for biology research these days. Recently we see dozens of papers published in top journals addressing this intersting field. In case you are not familiar with it, I quoted those lines full of jargons from Wikipedia:
| + | The whole process can be divided into the following steps: |
| − | <blockquote>CRISPRs are DNA loci containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a virus.<br>
| + | |
| − | The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of acquired immunity. CRISPR spacers recognize and silence these exogenous genetic elements like RNAi in eukaryotic organisms.<br> | + | |
| − | Since 2012, the CRISPR/Cas system has been used for gene editing (silencing, enhancing or changing specific genes) that even works in eukaryotes like mice and primates. By inserting a plasmid containing cas genes and specifically designed CRISPRs, an organism's genome can be cut at any desired location.<br>
| + | |
| − | '''-Wikipedia'''
| + | |
| − | </blockquote>
| + | |
| | | | |
| − | In short, CRISPR/Cas System is a tool to edit genes in '''live''' cells. Similar tools include TALEN(Transcription activator-like effector nuclease) and ZFN(Zinc Finger Nuclease). But CRISPR/Cas is superior than those methods in that CRISPR/Cas is guided by short RNA chain (~23bp), which is obviously easier to synthesize.<br>
| + | ==== Conserved Sequence Analysis ==== |
| − | Moreover, TALENs require a significantly longer time to construct<sup>[http://indepth.systembio.com/cas9-crispr-faq/what-is-the-difference-between-cas9-crispr-and-talen SystemBio]</sup>.
| + | |
| | | | |
| − | === CRISPR gRNA Basics ===
| + | We first extracted all conserved regions from the NIH HIV-1 Reference Genome. In this step, we found around 10 alternatives for the next process. Here all screening processes are done in a per-strain basis because of the high mutability of the HIV-1 virus. |
| | | | |
| − | As mentioned above, CRISPR/Cas9 Systems need a gRNA(Guide RNA) sequence to identify the target<sup>[http://www.nature.com/nprot/journal/v8/n11/full/nprot.2013.143.html ZhangFCas]</sup>. The gRNA is a 23bp long RNA beginning with a 3bp PAM(Protospacer Adjacent Motif) sequence. To effectively and specifically target a gene, the remaining 20bp of gRNA have to match the target sequence strictly. According to [http://crispr.mit.edu/about ZhangTool], the approximate quality of gRNA can be denoted as
| + | ==== Strip out sequences without PAM ==== |
| − | https://static.igem.org/mediawiki/parts/2/23/Equation-crispr.png .
| + | |
| | | | |
| − | Remember here that this equation bases only on an approximation of experimental data, and may differ from the actual situation.
| |
| | | | |
| − | === Designing the Sequence === | + | ====Select gRNA sequences with the best theoretical quality==== |
| | | | |
| − | We used a method derived from the method described in the paper by Feng Zhang<sup>[http://www.nature.com/nbt/journal/v31/n9/abs/nbt.2647.html ZhangFgRNA]</sup>.
| |
| | | | |
| − | The whole process can be divided into the following steps:
| |
| − | ==== Conserved Sequence Analysis ====
| |
| | | | |
| − | We first extracted all conserved regions from the NIH HBV Reference Genome. In this step, we found around 10 alternatives for the next process. Here all screening processes are done in a per-strain basis because of the high mutability of the HBV virus.
| + | |
| | + | |
| | + | |
| | + | ===Source=== |
| | + | |
| | + | AB010289-AB078031 in HBV_aligned Database |
| | | | |
| | ===References=== | | ===References=== |
We first extracted all conserved regions from the NIH HIV-1 Reference Genome. In this step, we found around 10 alternatives for the next process. Here all screening processes are done in a per-strain basis because of the high mutability of the HIV-1 virus.
